cedazuridine; decitabine
Generic: CEDAZURIDINE; DECITABINE·Brand: INQOVI
cedazuridine; decitabine: 1 clinical trial tracked.
cedazuridine; decitabine evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about cedazuridine; decitabine, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Primary endpoint: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Interventionalopen33 enrolledStarted 2023-02Completion 2028-0224 sites · Australia, Brazil, Canada, China…Novartis Pharmaceuticals